| ADR Ontology |
| ADR Term |
Neurofibrosarcomas |
| ADR ID |
BADD_A10512 |
| ADR Hierarchy |
|
| Description |
A malignant tumor that arises from small cutaneous nerves, is locally aggressive, and has a potential for metastasis. Characteristic histopathologic features include proliferating atypical spindle cells with slender wavy and pointed nuclei, hypocellular areas, and areas featuring organized whorls of fibroblastic proliferation. The most common primary sites are the extremities, retroperitoneum, and trunk. These tumors tend to present in childhood, often in association with NEUROFIBROMATOSIS 1. (From DeVita et al., Cancer: Principles & Practice of Oncology, 5th ed, p1662; Mayo Clin Proc 1990 Feb;65(2):164-72) | A malignant neurilemmoma with nerve sheath differentiation. It is often associated with NEUROFIBROMATOSIS 1 and RHABDOMYOSARCOMA. [MeSH] |
| MedDRA Code |
10029273 |
| MeSH ID |
D018319
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Neurofibrosarcoma | Neurofibrosarcomas | Sarcoma, Neurogenic | Neurogenic Sarcoma | Neurogenic Sarcomas | Sarcomas, Neurogenic | Malignant Peripheral Nerve Sheath Tumors | Neurilemmosarcoma | Neurilemmosarcomas | MPNST | Malignant Neurilemmoma | Malignant Neurilemmomas | Neurilemmoma, Malignant | Peripheral Nerve Sheath Tumors, Malignant | Malignant Neurilemoma | Malignant Neurilemomas | Neurilemoma, Malignant | Schwannoma, Malignant | Malignant Schwannoma | Malignant Schwannomas | Malignant Peripheral Nerve Sheath Tumor |
|
|
| Drugs Leading to the ADR |
| Drug ID | Drug Name | ADR Frequency (FAERS) | ADR Severity Grade (FAERS) | | BADD_D02257 | Trametinib | 0.000112% | | | BADD_D02493 | Selinexor | 0.000951% | |
| The 1th Page 1
Total 1 Pages
|
|
